Michael Makris։ New NEJM Paper Reports Results of Mim8 in Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about a recent article by Maria Elisa Mancuso et al, published in The New England Journal of Medicine (NEJM), adding։
”The Mim8 results paper was published today in the New England Journal of Medicine.
Mim8 works in the same way and is a direct competitor to emicizumab (Hemlibra).
The introduction of emicizumab has been the most impactful change in hemophilia care in the last 20-25 years.
Both Mim8 and emicizumab are bispecific antibodies. Is one better than the other in terms of efficacy? Only a randomised trial will tell us this, but nobody will do such a trial. I expect there will be lots of papers comparing the two products in a non-randomised way, with all the limitations that they bring.
In most countries, the introduction of a second similar drug will result in competition and lower prices, but I doubt this will be the case in the US.
The PDF of the paper is behind a paywall, but here is the graphical summary.”
Title: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
Authors: Maria Elisa Mancuso, Anthony K.C. Chan, Chandrakala Shanmukhaiah, Chuhl Joo Lyu, Joanna Zdziarska, Johnny Mahlangu, Lize F.D. van Vulpen, Pratima Chowdary, Renchi Yang, Steven R. Lentz, Tadashi Matsushita, Wan Hui Ong Clausen, Ilgiz Rakhmatullin, Johannes Oldenburg
Other posts featuring Michael Makris on Hemostasis Today.
-
Nov 2, 2026, 18:08Jonathan Penm: Antithrombotic Stewardship Optimizes VTE Prophylaxis in ICU Patients
-
Nov 2, 2026, 14:48Heghine Khachatryan: Vitamin B12 Replacement Choosing the Right Route for Each Patient
-
Nov 2, 2026, 14:28Anastasia Conti: ASH Global Research Award Backs New Directions in AML Research
-
Nov 2, 2026, 14:22Sara Zalghout: Linking Bacterial Virulence to NETosis and Thromboinflammation
-
Nov 2, 2026, 13:58Functional Iron Deficiency: From Iron Sequestration to Therapeutic Targeting
-
Nov 2, 2026, 13:56Jan Terje Andersen: Albumin Engineering Opens New Routes for Erythropoietin Delivery
-
Nov 2, 2026, 13:44Rishiraj Sinha: Strengthening ISBT–AABB Collaboration in Transfusion Medicine
-
Nov 2, 2026, 13:28Jeremiah Morris: Why Blood Detection Reagents Work Better on Dry Bloodstains
-
Nov 2, 2026, 12:38Maria Τektonidou: Machine Learning – A New Approach to CVD Risk in SLE